Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 10—October 2019

Sporotrichosis in the Highlands of Madagascar, 2013–20171

Tahinamandranto Rasamoelina, Danièle Maubon, Onivola Raharolahy, Harinjara Razanakoto, Njary Rakotozandrindrainy, Fetra Angelot Rakotomalala, Sébastien Bailly, Fandresena Sendrasoa, Irina Ranaivo, Malalaniaina Andrianarison, Benja Rakotonirina, Abel Andriantsimahavandy, Fahafahantsoa Rapelanoro Rabenja, Mala Rakoto Andrianarivelo, Lala Soavina Ramarozatovo, and Muriel CornetComments to Author 
Author affiliations: Centre d’Infectiologie Charles Mérieux, Université d’Antananarivo, Antananarivo, Madagascar (T. Rasamoelina, F.A. Rakotomalala, M.R. Andrianarivelo); University Grenoble Alpes, Grenoble, France (D. Maubon, S. Bailly, M. Cornet); Unité de Soins de Formation et de Recherche, Centre Hospitalier Universitaire Joseph Raseta Befelatanana, Antananarivo (O. Raharolahy, H. Razanakoto, F. Sendrasoa, I. Ranaivo, M. Andrianarison, F.R. Rabenja, L.S. Ramarozatovo); Unité Para-clinique de Formation et de Recherche, Centre Hospitalier Universitaire Joseph Ravoahangy, Antananarivo (N. Rakotozandrindrainya); Université d’Antananarivo, Antananarivo (B. Rakotonirina, A. Andriantsimahavandy); Pavillon Spécial A Centre Hospitalier Universitaire de Befelatanana, Antananarivo (L.S. Ramarozatovo)

Main Article

Table 4

MICs of 5 antimicrobial drugs for 46 Sporothrix schenckii isolates in the mycelium phase, from patients in Madagascar, 2013–2017*

Drug No. isolates with each MIC, μg/mL
MIC, μg/mL
<0.25 0.5 1 2 4 8 >16 GM 50% 90%
Posaconazole 10 11 13 6 1 5 0 0.78 1 4
Isavuconazole 1 0 7 8 13 17 0 3.35 4 8
Amphotericin B 14 10 9 8 3 0 2 0.7 0.5 2
Itraconazole 4 10 12 6 9 2 3 1.43 1 4
Terbinafine 38 3 2 1 2 0 0 0.14 ≤0.25 0.5

*MIC 50% and 90% represent the minimal concentrations of drug that inhibit the isolates by that percentage. GM, geometric mean.

Main Article

1Preliminary results from this study were presented at the 20th ISHAM Conference; June 29–July 5, 2018; Amsterdam, the Netherlands (abstract no. S1.4d).

Page created: September 17, 2019
Page updated: September 17, 2019
Page reviewed: September 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.